Literature DB >> 3683699

Perioperative morbidity associated with operative resection of craniopharyngioma: a review of ten years experience.

M N Bucci1, L S Chin, J T Hoff.   

Abstract

A ten-year review of perioperative morbidity after operative resection of craniopharyngioma is presented. From 1974 to 1983, 23 patients underwent a total of 34 operations. Patients were subdivided into 95% or greater resection and partial resection groups. Features compared between the two groups included sodium, glucose, temperature, diabetes insipidus, major complications, neurological deficits and death. Patients undergoing 95% or greater resection had significant fluctuations in sodium, temperature and glucose (p less than .01). Diabetes insipidus and major postoperative complications were also significantly elevated in the 95% or greater resection group (p less than .05). Therefore, the extent of surgical resection correlated well with the degree of metabolic dysfunction and major postoperative complications. Careful assessment of surgical morbidity is warranted in the management of patients with craniopharyngioma.

Entities:  

Mesh:

Year:  1987        PMID: 3683699     DOI: 10.1055/s-2008-1054081

Source DB:  PubMed          Journal:  Neurochirurgia (Stuttg)        ISSN: 0028-3819


  2 in total

1.  Choice of fluid therapy in patients of craniopharyngioma in the perioperative period: A hospital-based preliminary study.

Authors:  K K Mukherjee; Pinaki Dutta; Apinderpreet Singh; Prakamya Gupta; Anand Srinivasan; Hemant Bhagat; S N Mathuriya; Viral N Shah; Anil Bhansali
Journal:  Surg Neurol Int       Date:  2014-07-08

2.  Effect of Perioperative Fluids on Serum Osmolality and Serum Sodium in Patients Undergoing Transcranial Excision of Craniopharyngioma: A Prospective Randomized Controlled Trial.

Authors:  Pranshuta Sabharwal; Nidhi Panda; Neeru Sahni; Ashish Kumar Sahoo; Ankur Luthra; Rajeev Chauhan; Hemant Bhagat; Pinaki Dutta
Journal:  Asian J Neurosurg       Date:  2021-02-23
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.